Data have shown that second-generation protease inhibitor Faldaprevir, when used in combination with Pegylated Interferon and Ribavirin, was effective even with the presence of naturally-occurring mutant variants of the hepatitis C virus ( HCV ), such as the NS3 Q80K polymorphism.
The Q80K mutant was detected in 23% ( 49/127, STARTVerso ) and 40% ( 159/398, STARTVerso ) of genotype-1a infected patients. Its presence was found to have no effect on the chances of viral cure ( SVR12 ) in genotype-1 infected hepatitis C patients treated with Faldaprevir plus PegInterferon and Ribavirin.
These data were presented at HEP DART 2013 ( Big Island, Hawaii ).
The HCV NS3/4A protease is essential for viral replication and is a key target for direct acting antiviral ( DAA ) treatments such as Faldaprevir. The NS3 Q80K variant is the most commonly observed NS3 polymorphism in genotype-1a HCV and has been reported in up to 47% of genotype-1a infected patients. The variation in frequency is influenced by the geography, with the prevalence of Q80K being particularly high in the USA. ( Xagena )
Source: Boehringer-Ingelheim, 2013